Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Gene Variant Descriptions||FGFR3 fusion indicates a fusion of the FGFR3 gene, but the fusion partner is unknown.|
|Associated Drug Resistance|
|Molecular Profile||Protein Effect||Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 fusion||urinary bladder cancer||sensitive||AZD4547||Preclinical - Cell culture||Actionable||In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940).||27550940|
|FGFR3 fusion||Advanced Solid Tumor||predicted - sensitive||Debio 1347||Phase I||Actionable||In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).||30745300|
|FGFR3 fusion||Advanced Solid Tumor||predicted - sensitive||AZD4547||Phase II||Actionable||In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).||detail...|
|FGFR3 fusion||transitional cell carcinoma||sensitive||Infigratinib||Phase I||Actionable||In a Phase I trial, Infigratinib (BGJ398) treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).||detail...|
|FGFR3 fusion||Advanced Solid Tumor||predicted - sensitive||Futibatinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, TAS-120 demonstrated growth inhibition and reduced FGFR phosphorylation in human cancer cell lines and xenograft models harboring FGFR mutations (Mol Cancer Ther 2013;12(11 Suppl):A270).||detail...|
|FGFR3 fusion||transitional cell carcinoma||predicted - sensitive||Erdafitinib||Phase I||Actionable||In a Phase I trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 46% (12/26) in patients with urothelial carcinoma harboring FGFR genomic alterations, including 17 with FGFR3 mutations, and 11 with FGFR2 and/or FGFR3 fusions (PMID: 31088831; NCT01703481).||31088831|
|FGFR3 fusion||transitional cell carcinoma||predicted - sensitive||Docetaxel + Vofatamab||Phase Ib/II||Actionable||In a Phase I/II trial, Vofatamab (B-701) in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).||detail...|